Biomotion Sciences. Ordinary Shares SLXN 深 滬
等待開盤 09-18 09:30:00 美东时间
3.43
-0.100
-2.83%
華盛通- 最 高3.57
- 今 開3.50
- 成交量 15.43万股
- 最 低 3.37
- 昨 收 3.53
- 總市值 2981.49万
- 52周最高 97.335
- 市盈率 靜 --
- 換手率 1.77%
- 52周最低 3.37
- 委 比 31.97%
- 總股本 869.24万
- 歷史最高 627.75
- 量 比 0.08
- 振 幅 5.67%
- 歷史最低 3.37
- 每 手 1
- 風險率 1.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Is Silexion Therapeutics Stock (SLXN) Up 190% Today?
Silexion Therapeutics stock was up on Thursday after the company posted positiv...
09-11 20:15
Market-Moving News for September 11th
SLXN: 50% | Silexion Highlights Preclinical Data Of SIL204 Supporting Dual-Route Treatment Strategy With Phase 2/3 Trial On Track For 2026 VNCE: 242% | Vince Holding Q2 Adj. EPS $0.38 Beats $(0.10)
09-11 19:26
Silexion's SIL204 Reaches All Major Sites Of Pancreatic Cancer Spread And Cuts Tumor Burden In Preclinical Study
Silexion Therapeutics Corp. (NASDAQ:SLXN), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical data demonstrating that
09-11 19:01
Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
Silexion Therapeutics Corp. announced a public offering of 1.5 million ordinary shares and warrants, with total gross proceeds of $6 million. Proceeds will fund pre-clinical studies and corporate purposes. The offering includes Series A and B warrants, with differing expiration periods. H.C. Wainwright & Co. is the placement agent. The offering is under SEC registration (File No. 333-290074). Silexion focuses on RNAi therapies for KRAS-driven can...
09-11 13:17
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
Silexion Therapeutics announced successful preclinical data for SIL204, demonstrating effective distribution to liver, peritoneum, and lungs, with measurable tumor burden reductions. The study validates the systemic component of their dual-route administration strategy, targeting both primary tumors and metastatic disease. Silexion plans to initiate Phase 2/3 trials in H1 2026, following regulatory submissions in Q4 2025 and Q1 2026.
09-11 11:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 80.7% to $1.35 during Tues...
09-10 01:06
Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
Silexion Therapeutics has selected AMS Advanced Medical Services GmbH as their CRO to support Phase 2/3 trials for SIL204, a next-generation siRNA candidate targeting KRAS-driven solid tumors. AMS, with over 28 years of experience in oncology trials, will assist in regulatory submissions to the Israel Ministry of Health by Q4 2025 and the EU by Q1 2026, with trials expected to begin in H1 2026. SIL204 recently showed 97% inhibition rates in precl...
09-04 13:25
Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
Silexion Therapeutics Corp. (NASDAQ: SLXN), specializing in RNA interference (RNAi) therapies for KRAS-driven cancers, announced that its senior management will present at the 27th Annual H.C. Wainwright Global Investment Conference on September 8-10, 2025, in New York City. The company's presentation will take place on September 10, 2025, at 2:00 PM ET. An updated presentation is available on the company's investor site. Silexion management will...
09-02 12:45
Silexion Therapeutics Executes Reverse Stock Split
Silexion Therapeutics ( ($SLXN) ) has shared an announcement. On July 28, 2025,...
08-21 05:19
Silexion Therapeutics Increases Authorized Share Capital
Silexion Therapeutics ( ($SLXN) ) has provided an announcement. At the extraord...
08-19 22:27
